Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 2
2020 1
2021 3
2022 7
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy in renal cell carcinoma.
Navani V, Heng DYC. Navani V, et al. Lancet Oncol. 2023 Nov;24(11):1164-1166. doi: 10.1016/S1470-2045(23)00473-4. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844599 No abstract available.
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
Ernst MS, Navani V, Wells JC, Donskov F, Basappa N, Labaki C, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, McKay RR, Parnis F, Suarez C, Yuasa T, Lalani AK, Alva A, Bjarnason GA, Choueiri TK, Heng DYC. Ernst MS, et al. Among authors: navani v. Eur Urol. 2023 Jul;84(1):109-116. doi: 10.1016/j.eururo.2023.01.001. Epub 2023 Jan 26. Eur Urol. 2023. PMID: 36707357 Free article.
Melanoma: An immunotherapy journey from bench to bedside.
Navani V, Graves MC, Mandaliya H, Hong M, van der Westhuizen A, Martin J, Bowden NA. Navani V, et al. Cancer Treat Res. 2022;183:49-89. doi: 10.1007/978-3-030-96376-7_2. Cancer Treat Res. 2022. PMID: 35551656
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K, Navani V, Ernst MS, Wells JC, Meza L, Pal SK, Lee JL, Li H, Agarwal N, Alva AS, Hansen AR, Basappa NS, Szabados B, Powles T, Tran B, Hocking CM, Beuselinck B, Yuasa T, Choueiri TK, Heng DYC. Takemura K, et al. Among authors: navani v. J Urol. 2023 Apr;209(4):701-709. doi: 10.1097/JU.0000000000003132. Epub 2022 Dec 27. J Urol. 2023. PMID: 36573926
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.
Stukalin I, Navani V, Gupta M, Ruan Y, Boyne DJ, O'Sullivan DE, Meyers DE, Goutam S, Sander M, Ewanchuk BW, Brenner DR, Suo A, Cheung WY, Heng DYC, Monzon JG, Cheng T. Stukalin I, et al. Among authors: navani v. Oncologist. 2023 Sep 7;28(9):812-822. doi: 10.1093/oncolo/oyad073. Oncologist. 2023. PMID: 37011230 Free PMC article.
28 results